Arbutus Biopharma Corp (ABUS)vsRegeneron Pharmaceuticals Inc (REGN)
ABUS
Arbutus Biopharma Corp
$5.12
0.00%
HEALTHCARE · Cap: $1.01B
REGN
Regeneron Pharmaceuticals Inc
$781.49
-1.48%
HEALTHCARE · Cap: $80.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 8449% more annual revenue ($15.53B vs $181.72M). ABUS leads profitability with a 84.2% profit margin vs 27.9%. ABUS trades at a lower P/E of 6.5x. REGN earns a higher WallStSmart Score of 66/100 (B-).
ABUS
Hold43
out of 100
Grade: D
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABUS.
Margin of Safety
+44.4%
Fair Value
$1404.34
Current Price
$781.49
$622.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 59 in profit
Keeps 84 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 90.6%
Negative free cash flow — burning cash
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABUS
The strongest argument for ABUS centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 84.2% and operating margin at -567.0%.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : ABUS
The primary concerns for ABUS are EPS Growth, Market Cap, Revenue Growth.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ABUS profiles as a declining stock while REGN is a growth play — different risk/reward profiles.
ABUS carries more volatility with a beta of 0.62 — expect wider price swings.
REGN is growing revenue faster at 16.7% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (66/100 vs 43/100), backed by strong 27.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arbutus Biopharma Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?